 Brian Freed
Concepts (523)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HLA-DRB1 Chains | 8 | 2025 | 112 | 1.780 |
Why?
| | T-Lymphocytes | 22 | 2025 | 1998 | 1.430 |
Why?
| | Epitopes | 4 | 2016 | 480 | 1.220 |
Why?
| | HLA Antigens | 9 | 2024 | 237 | 0.920 |
Why?
| | Genetic Predisposition to Disease | 6 | 2016 | 2417 | 0.890 |
Why?
| | Lymphocyte Activation | 19 | 2006 | 1150 | 0.860 |
Why?
| | Arthritis, Rheumatoid | 4 | 2025 | 1164 | 0.850 |
Why?
| | Interleukin-2 | 16 | 2005 | 454 | 0.770 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1455 | 0.740 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2022 | 87 | 0.730 |
Why?
| | Hydroquinones | 6 | 2003 | 29 | 0.700 |
Why?
| | Kidney Transplantation | 20 | 2019 | 700 | 0.690 |
Why?
| | Back Pain | 1 | 2021 | 49 | 0.680 |
Why?
| | HLA-B Antigens | 3 | 2024 | 62 | 0.660 |
Why?
| | HLA-DR Antigens | 5 | 2020 | 228 | 0.610 |
Why?
| | Alleles | 8 | 2025 | 888 | 0.580 |
Why?
| | Tars | 3 | 2006 | 5 | 0.570 |
Why?
| | Graft Rejection | 14 | 2019 | 620 | 0.550 |
Why?
| | Acrolein | 2 | 2007 | 23 | 0.510 |
Why?
| | Immunosuppressive Agents | 13 | 2017 | 890 | 0.490 |
Why?
| | Cyclosporins | 11 | 1991 | 76 | 0.490 |
Why?
| | Vimentin | 2 | 2016 | 52 | 0.490 |
Why?
| | Peptides, Cyclic | 2 | 2016 | 259 | 0.440 |
Why?
| | Catechols | 4 | 2003 | 14 | 0.440 |
Why?
| | Histocompatibility Antigens Class I | 3 | 2022 | 202 | 0.420 |
Why?
| | Peptides | 2 | 2016 | 980 | 0.420 |
Why?
| | Transplantation, Haploidentical | 2 | 2024 | 22 | 0.410 |
Why?
| | Tissue Donors | 6 | 2018 | 417 | 0.400 |
Why?
| | Histocompatibility Antigens Class II | 5 | 2022 | 368 | 0.390 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 250 | 0.380 |
Why?
| | Fetal Blood | 6 | 2024 | 327 | 0.380 |
Why?
| | Cord Blood Stem Cell Transplantation | 5 | 2016 | 99 | 0.370 |
Why?
| | Immune Tolerance | 4 | 2025 | 362 | 0.370 |
Why?
| | Smoking | 5 | 2011 | 1633 | 0.360 |
Why?
| | DNA | 7 | 2007 | 1458 | 0.360 |
Why?
| | Smoke | 5 | 2007 | 144 | 0.360 |
Why?
| | B-Lymphocytes | 7 | 2021 | 846 | 0.360 |
Why?
| | Double-Blind Method | 2 | 2024 | 1981 | 0.350 |
Why?
| | Humans | 93 | 2024 | 136783 | 0.340 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 849 | 0.340 |
Why?
| | Ribonucleotide Reductases | 2 | 2000 | 31 | 0.320 |
Why?
| | Arachis | 1 | 2010 | 112 | 0.310 |
Why?
| | Graft Survival | 9 | 2017 | 533 | 0.310 |
Why?
| | Immunoglobulin E | 1 | 2010 | 341 | 0.300 |
Why?
| | Immunoglobulin G | 4 | 2013 | 886 | 0.300 |
Why?
| | Peanut Hypersensitivity | 1 | 2010 | 146 | 0.300 |
Why?
| | Cells, Cultured | 11 | 2019 | 4194 | 0.280 |
Why?
| | Lymphocytes | 3 | 2013 | 395 | 0.270 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2007 | 26 | 0.270 |
Why?
| | Isoantibodies | 3 | 2017 | 60 | 0.270 |
Why?
| | Disease Models, Animal | 5 | 2021 | 4279 | 0.260 |
Why?
| | Plants, Toxic | 3 | 2000 | 24 | 0.250 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2016 | 1092 | 0.250 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2006 | 47 | 0.250 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2006 | 42 | 0.250 |
Why?
| | Immune System | 2 | 2021 | 177 | 0.240 |
Why?
| | Histocompatibility Testing | 7 | 2019 | 126 | 0.240 |
Why?
| | Mental Disorders | 1 | 2014 | 1075 | 0.240 |
Why?
| | Tuberculosis | 2 | 2023 | 279 | 0.240 |
Why?
| | Flow Cytometry | 5 | 2016 | 1181 | 0.240 |
Why?
| | Mycobacterium tuberculosis | 2 | 2023 | 312 | 0.240 |
Why?
| | Enzyme Inhibitors | 2 | 2000 | 838 | 0.230 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2024 | 615 | 0.230 |
Why?
| | Ethylmaleimide | 3 | 1991 | 18 | 0.230 |
Why?
| | Antibodies | 3 | 2019 | 412 | 0.230 |
Why?
| | Haplotypes | 3 | 2014 | 490 | 0.220 |
Why?
| | Ganciclovir | 4 | 1997 | 53 | 0.220 |
Why?
| | Cell Line | 10 | 2016 | 2836 | 0.210 |
Why?
| | Cytomegalovirus Infections | 5 | 1997 | 191 | 0.210 |
Why?
| | Gene Frequency | 3 | 2019 | 520 | 0.210 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2014 | 3709 | 0.200 |
Why?
| | Islets of Langerhans | 3 | 1994 | 803 | 0.200 |
Why?
| | Glutamic Acid | 1 | 2025 | 248 | 0.200 |
Why?
| | HLA-A Antigens | 1 | 2022 | 55 | 0.200 |
Why?
| | Collagen | 1 | 2025 | 445 | 0.190 |
Why?
| | HLA-C Antigens | 1 | 2022 | 35 | 0.190 |
Why?
| | Interferon-gamma | 3 | 2005 | 790 | 0.190 |
Why?
| | Cigarette Smoking | 1 | 2023 | 101 | 0.190 |
Why?
| | Histocompatibility Antigens | 1 | 2022 | 106 | 0.190 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2005 | 1242 | 0.180 |
Why?
| | Protein Binding | 3 | 2016 | 2223 | 0.180 |
Why?
| | Cyclosporine | 5 | 1998 | 268 | 0.180 |
Why?
| | Receptors, KIR | 2 | 2022 | 98 | 0.180 |
Why?
| | Enoxaparin | 1 | 2022 | 62 | 0.180 |
Why?
| | In Vitro Techniques | 9 | 2005 | 1089 | 0.180 |
Why?
| | Central Tolerance | 1 | 2021 | 10 | 0.180 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2021 | 40 | 0.180 |
Why?
| | Receptors, CXCR4 | 1 | 2021 | 85 | 0.170 |
Why?
| | Transplantation, Homologous | 9 | 2019 | 415 | 0.170 |
Why?
| | DNA-Binding Proteins | 2 | 2011 | 1500 | 0.170 |
Why?
| | HLA-DRB4 Chains | 1 | 2020 | 6 | 0.170 |
Why?
| | Heterografts | 1 | 2021 | 138 | 0.170 |
Why?
| | Mice | 18 | 2025 | 17731 | 0.170 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2603 | 0.170 |
Why?
| | Receptors, Interleukin-2 | 5 | 2003 | 66 | 0.170 |
Why?
| | Evolution, Molecular | 1 | 2024 | 488 | 0.170 |
Why?
| | Brain Ischemia | 1 | 2024 | 341 | 0.170 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2020 | 189 | 0.160 |
Why?
| | Nickel | 1 | 2020 | 63 | 0.160 |
Why?
| | Cell Division | 4 | 1997 | 796 | 0.160 |
Why?
| | Trace Elements | 1 | 2020 | 51 | 0.160 |
Why?
| | Receptors, Antigen, B-Cell | 2 | 2021 | 130 | 0.160 |
Why?
| | Bias | 1 | 2021 | 218 | 0.160 |
Why?
| | alpha 1-Antitrypsin | 1 | 2020 | 108 | 0.160 |
Why?
| | Transcription Factors | 2 | 2005 | 1714 | 0.160 |
Why?
| | Cell Cycle Proteins | 1 | 2003 | 611 | 0.150 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2019 | 17 | 0.150 |
Why?
| | Immunotherapy | 2 | 2021 | 640 | 0.150 |
Why?
| | Vascular System Injuries | 1 | 2019 | 71 | 0.150 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2020 | 63 | 0.150 |
Why?
| | Adrenocortical Carcinoma | 1 | 2020 | 65 | 0.150 |
Why?
| | Animals | 26 | 2025 | 36768 | 0.150 |
Why?
| | Unrelated Donors | 2 | 2024 | 39 | 0.150 |
Why?
| | Tumor Microenvironment | 2 | 2020 | 671 | 0.150 |
Why?
| | Insulin | 3 | 1994 | 2399 | 0.150 |
Why?
| | Tacrolimus | 2 | 2017 | 199 | 0.150 |
Why?
| | HEK293 Cells | 2 | 2022 | 728 | 0.140 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 24 | 0.140 |
Why?
| | Transcription, Genetic | 2 | 2003 | 1453 | 0.140 |
Why?
| | Herpesvirus 4, Human | 1 | 2018 | 167 | 0.140 |
Why?
| | Hydrogen Peroxide | 3 | 1988 | 320 | 0.140 |
Why?
| | Cell Transplantation | 1 | 1997 | 37 | 0.140 |
Why?
| | Antiviral Agents | 3 | 2020 | 736 | 0.140 |
Why?
| | Donor Selection | 1 | 2018 | 77 | 0.140 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2018 | 99 | 0.140 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 210 | 0.130 |
Why?
| | Proinsulin | 1 | 1997 | 52 | 0.130 |
Why?
| | Hypersensitivity | 1 | 2020 | 257 | 0.130 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2016 | 376 | 0.130 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 124 | 0.130 |
Why?
| | Carcinogenesis | 1 | 2018 | 217 | 0.130 |
Why?
| | Amino Acid Sequence | 4 | 2016 | 2145 | 0.130 |
Why?
| | Benzoquinones | 1 | 1997 | 48 | 0.130 |
Why?
| | Transplantation Conditioning | 1 | 2018 | 170 | 0.130 |
Why?
| | Mice, Inbred BALB C | 5 | 2021 | 1267 | 0.130 |
Why?
| | Complement System Proteins | 1 | 2019 | 327 | 0.130 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2016 | 26 | 0.130 |
Why?
| | Genetic Variation | 2 | 2015 | 985 | 0.130 |
Why?
| | Female | 29 | 2024 | 72840 | 0.130 |
Why?
| | Interleukin-1 | 1 | 2000 | 963 | 0.130 |
Why?
| | HLA-DQ beta-Chains | 1 | 2016 | 63 | 0.130 |
Why?
| | Dextrans | 1 | 2016 | 84 | 0.130 |
Why?
| | Collagen Type II | 1 | 2016 | 53 | 0.130 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2012 | 225 | 0.120 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2019 | 201 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1055 | 0.120 |
Why?
| | Autoantibodies | 4 | 2021 | 1500 | 0.120 |
Why?
| | Adult | 19 | 2024 | 37616 | 0.120 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2016 | 387 | 0.120 |
Why?
| | Retrospective Studies | 10 | 2024 | 15564 | 0.120 |
Why?
| | Genotype | 3 | 2022 | 1919 | 0.120 |
Why?
| | Genetic Therapy | 1 | 1997 | 296 | 0.120 |
Why?
| | Stroke | 1 | 2024 | 1129 | 0.120 |
Why?
| | Resting Phase, Cell Cycle | 2 | 2006 | 15 | 0.120 |
Why?
| | Protein Kinase C | 1 | 1996 | 260 | 0.110 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 459 | 0.110 |
Why?
| | Methylprednisolone | 3 | 1991 | 85 | 0.110 |
Why?
| | Kidney Failure, Chronic | 2 | 2017 | 565 | 0.110 |
Why?
| | Clonal Anergy | 1 | 1994 | 52 | 0.110 |
Why?
| | G1 Phase | 2 | 2006 | 71 | 0.110 |
Why?
| | Endothelial Cells | 1 | 2019 | 778 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 804 | 0.110 |
Why?
| | Autoimmunity | 2 | 2021 | 908 | 0.110 |
Why?
| | Tobacco Smoke Pollution | 1 | 1997 | 285 | 0.110 |
Why?
| | Immunoglobulin Isotypes | 1 | 2013 | 34 | 0.110 |
Why?
| | Lymphocyte Culture Test, Mixed | 7 | 1996 | 50 | 0.110 |
Why?
| | Tumor Cells, Cultured | 4 | 2020 | 953 | 0.110 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 451 | 0.100 |
Why?
| | Male | 23 | 2024 | 67361 | 0.100 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 25 | 0.100 |
Why?
| | Cell Cycle | 3 | 2006 | 601 | 0.100 |
Why?
| | Models, Biological | 1 | 2020 | 1769 | 0.100 |
Why?
| | Dried Blood Spot Testing | 1 | 2013 | 103 | 0.100 |
Why?
| | C-Reactive Protein | 2 | 1987 | 411 | 0.100 |
Why?
| | Radioimmunoassay | 5 | 1990 | 173 | 0.100 |
Why?
| | Indoles | 1 | 1996 | 410 | 0.100 |
Why?
| | Models, Animal | 2 | 2013 | 384 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 864 | 0.100 |
Why?
| | Transduction, Genetic | 1 | 2013 | 126 | 0.100 |
Why?
| | Middle Aged | 13 | 2024 | 33200 | 0.100 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 51 | 0.100 |
Why?
| | Pulmonary Fibrosis | 1 | 2016 | 400 | 0.100 |
Why?
| | Islets of Langerhans Transplantation | 1 | 1992 | 64 | 0.100 |
Why?
| | Leukemia L1210 | 1 | 1992 | 8 | 0.100 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 326 | 0.090 |
Why?
| | Chagas Disease | 1 | 2012 | 43 | 0.090 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2012 | 337 | 0.090 |
Why?
| | Postoperative Complications | 5 | 2017 | 2624 | 0.090 |
Why?
| | Beryllium | 2 | 2005 | 153 | 0.090 |
Why?
| | Lung | 4 | 2007 | 4065 | 0.090 |
Why?
| | Bronchiolitis Obliterans | 1 | 2012 | 69 | 0.090 |
Why?
| | Blood Specimen Collection | 1 | 2011 | 38 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2025 | 2162 | 0.090 |
Why?
| | Blood Banks | 1 | 2011 | 41 | 0.090 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2011 | 14 | 0.090 |
Why?
| | Child, Preschool | 6 | 2014 | 11069 | 0.090 |
Why?
| | Colorectal Neoplasms | 1 | 2019 | 792 | 0.090 |
Why?
| | Transplantation Chimera | 1 | 2011 | 54 | 0.090 |
Why?
| | Fibroblasts | 2 | 1994 | 989 | 0.090 |
Why?
| | Maleimides | 1 | 1991 | 23 | 0.090 |
Why?
| | Calcium | 2 | 1994 | 1197 | 0.090 |
Why?
| | International Cooperation | 1 | 2011 | 198 | 0.090 |
Why?
| | Mice, Knockout | 5 | 2021 | 2999 | 0.090 |
Why?
| | Receptors, Transferrin | 2 | 2003 | 24 | 0.090 |
Why?
| | Chromatography, High Pressure Liquid | 7 | 2005 | 591 | 0.090 |
Why?
| | Spleen | 1 | 2013 | 513 | 0.090 |
Why?
| | Serine Endopeptidases | 2 | 2022 | 123 | 0.090 |
Why?
| | Skin Tests | 1 | 2010 | 101 | 0.080 |
Why?
| | Mitogens | 2 | 1988 | 61 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1686 | 0.080 |
Why?
| | Lymph Nodes | 1 | 2013 | 492 | 0.080 |
Why?
| | Cesarean Section | 1 | 2011 | 185 | 0.080 |
Why?
| | Antibody Formation | 1 | 1991 | 298 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1683 | 0.080 |
Why?
| | Hematopoietic Stem Cells | 1 | 2013 | 400 | 0.080 |
Why?
| | Siblings | 1 | 2010 | 228 | 0.080 |
Why?
| | Jurkat Cells | 2 | 2000 | 134 | 0.080 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2007 | 22 | 0.080 |
Why?
| | Nicotine | 2 | 2023 | 336 | 0.080 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1434 | 0.080 |
Why?
| | Base Sequence | 3 | 2012 | 2180 | 0.080 |
Why?
| | Survival Rate | 5 | 2017 | 1969 | 0.080 |
Why?
| | HLA-DQ Antigens | 2 | 2000 | 181 | 0.080 |
Why?
| | Cricetinae | 3 | 1994 | 288 | 0.080 |
Why?
| | Disease Susceptibility | 1 | 2011 | 344 | 0.080 |
Why?
| | Immunoglobulins, Intravenous | 3 | 1995 | 132 | 0.080 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2016 | 653 | 0.080 |
Why?
| | Lung Transplantation | 1 | 2012 | 308 | 0.070 |
Why?
| | Cell Survival | 3 | 1997 | 1117 | 0.070 |
Why?
| | Allografts | 2 | 2019 | 146 | 0.070 |
Why?
| | Phytohemagglutinins | 4 | 1991 | 30 | 0.070 |
Why?
| | Anemia, Sickle Cell | 1 | 2012 | 265 | 0.070 |
Why?
| | Adolescent | 7 | 2014 | 21463 | 0.070 |
Why?
| | Amino Acids | 1 | 2011 | 500 | 0.070 |
Why?
| | Research Design | 1 | 2014 | 1107 | 0.070 |
Why?
| | Mice, Nude | 2 | 2020 | 692 | 0.070 |
Why?
| | Genetic Linkage | 2 | 2006 | 298 | 0.070 |
Why?
| | Molecular Sequence Data | 3 | 2012 | 2903 | 0.070 |
Why?
| | Mice, Inbred NOD | 2 | 2021 | 601 | 0.070 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 209 | 0.070 |
Why?
| | Cell Differentiation | 4 | 2021 | 1980 | 0.070 |
Why?
| | Isoantigens | 1 | 1987 | 15 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2019 | 913 | 0.070 |
Why?
| | Aged | 6 | 2024 | 23729 | 0.070 |
Why?
| | Transcription Factor AP-1 | 1 | 2007 | 92 | 0.070 |
Why?
| | NFATC Transcription Factors | 1 | 2007 | 95 | 0.070 |
Why?
| | Cloning, Molecular | 2 | 1998 | 534 | 0.060 |
Why?
| | Follow-Up Studies | 5 | 2018 | 5115 | 0.060 |
Why?
| | Kidney Function Tests | 2 | 2017 | 159 | 0.060 |
Why?
| | Lung Diseases | 2 | 2006 | 768 | 0.060 |
Why?
| | HLA-B15 Antigen | 1 | 2006 | 13 | 0.060 |
Why?
| | Aldehydes | 1 | 2007 | 144 | 0.060 |
Why?
| | Enzyme Induction | 1 | 2006 | 90 | 0.060 |
Why?
| | Muromonab-CD3 | 2 | 1997 | 20 | 0.060 |
Why?
| | Sequence Homology | 1 | 2006 | 40 | 0.060 |
Why?
| | Prognosis | 4 | 2017 | 4018 | 0.060 |
Why?
| | Bone Marrow | 2 | 2021 | 286 | 0.060 |
Why?
| | Butylated Hydroxytoluene | 1 | 2006 | 38 | 0.060 |
Why?
| | Neoplasms | 1 | 2021 | 2644 | 0.060 |
Why?
| | Microspheres | 1 | 2006 | 137 | 0.060 |
Why?
| | HLA-DP Antigens | 1 | 2005 | 33 | 0.060 |
Why?
| | Cysteine | 1 | 2007 | 205 | 0.060 |
Why?
| | Autoantigens | 2 | 2021 | 428 | 0.060 |
Why?
| | Phospholipases A | 1 | 2006 | 102 | 0.060 |
Why?
| | Phenotype | 3 | 2021 | 3199 | 0.060 |
Why?
| | Arginine | 1 | 2007 | 271 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2020 | 2473 | 0.060 |
Why?
| | Biliary Atresia | 1 | 2007 | 163 | 0.060 |
Why?
| | Transfection | 2 | 1998 | 945 | 0.060 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2005 | 132 | 0.060 |
Why?
| | Phenols | 1 | 2006 | 100 | 0.060 |
Why?
| | Child | 5 | 2014 | 21968 | 0.060 |
Why?
| | Treatment Outcome | 5 | 2024 | 10764 | 0.060 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2004 | 32 | 0.060 |
Why?
| | Arteriosclerosis | 1 | 2005 | 88 | 0.060 |
Why?
| | Chemokines, CXC | 1 | 2004 | 70 | 0.060 |
Why?
| | Acetylcysteine | 1 | 2005 | 145 | 0.060 |
Why?
| | Antigen Presentation | 1 | 2005 | 215 | 0.060 |
Why?
| | Skin Transplantation | 1 | 2025 | 85 | 0.060 |
Why?
| | Reoperation | 3 | 1998 | 565 | 0.060 |
Why?
| | Young Adult | 3 | 2024 | 13126 | 0.050 |
Why?
| | Structure-Activity Relationship | 3 | 1991 | 573 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2011 | 3537 | 0.050 |
Why?
| | Agglutination | 2 | 1997 | 5 | 0.050 |
Why?
| | Amino Acid Substitution | 1 | 2025 | 309 | 0.050 |
Why?
| | Berylliosis | 1 | 2005 | 186 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 5749 | 0.050 |
Why?
| | Pandemics | 2 | 2024 | 1619 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2025 | 286 | 0.050 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2003 | 37 | 0.050 |
Why?
| | Concanavalin A | 3 | 1988 | 76 | 0.050 |
Why?
| | E2F Transcription Factors | 1 | 2003 | 60 | 0.050 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2003 | 98 | 0.050 |
Why?
| | Lectins, C-Type | 1 | 2003 | 67 | 0.050 |
Why?
| | Mesocricetus | 2 | 1992 | 39 | 0.050 |
Why?
| | Glomerular Filtration Rate | 2 | 2017 | 744 | 0.050 |
Why?
| | Risk Factors | 6 | 2017 | 10331 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 379 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2015 | 319 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2006 | 657 | 0.050 |
Why?
| | Cell Line, Transformed | 2 | 1992 | 145 | 0.050 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 396 | 0.050 |
Why?
| | Phosphoproteins | 1 | 2005 | 338 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2004 | 346 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2831 | 0.050 |
Why?
| | Biomarkers | 2 | 2019 | 4158 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2003 | 139 | 0.050 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 1987 | 172 | 0.050 |
Why?
| | Cell Communication | 2 | 2013 | 314 | 0.050 |
Why?
| | Reactive Oxygen Species | 1 | 2005 | 618 | 0.050 |
Why?
| | Drug Synergism | 2 | 1996 | 378 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2022 | 248 | 0.050 |
Why?
| | Neutrophils | 2 | 2005 | 1234 | 0.050 |
Why?
| | T-Lymphocyte Subsets | 2 | 2016 | 425 | 0.050 |
Why?
| | Leukemia | 2 | 2012 | 238 | 0.040 |
Why?
| | Chimerism | 1 | 2021 | 31 | 0.040 |
Why?
| | Antioxidants | 2 | 2006 | 578 | 0.040 |
Why?
| | Apoptosis | 2 | 2020 | 2548 | 0.040 |
Why?
| | Iron Chelating Agents | 1 | 2000 | 18 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 87 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 75 | 0.040 |
Why?
| | Cell Separation | 2 | 2011 | 318 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2001 | 189 | 0.040 |
Why?
| | Biopsy | 2 | 2019 | 1126 | 0.040 |
Why?
| | Virus Internalization | 1 | 2020 | 47 | 0.040 |
Why?
| | Kidney | 4 | 2019 | 1463 | 0.040 |
Why?
| | Ganglionic Stimulants | 1 | 2000 | 14 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2023 | 387 | 0.040 |
Why?
| | Free Radicals | 1 | 2000 | 108 | 0.040 |
Why?
| | Leukocyte Elastase | 1 | 2020 | 76 | 0.040 |
Why?
| | Dimerization | 1 | 2000 | 198 | 0.040 |
Why?
| | Antithrombins | 1 | 2020 | 59 | 0.040 |
Why?
| | Biological Evolution | 1 | 2024 | 464 | 0.040 |
Why?
| | RNA | 2 | 1997 | 924 | 0.040 |
Why?
| | Extracellular Traps | 1 | 2020 | 53 | 0.040 |
Why?
| | Blotting, Western | 2 | 2004 | 1225 | 0.040 |
Why?
| | Antigens, CD | 1 | 2003 | 522 | 0.040 |
Why?
| | Gene Expression | 1 | 2005 | 1499 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 367 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 664 | 0.040 |
Why?
| | Arthroplasty, Replacement | 1 | 2020 | 40 | 0.040 |
Why?
| | Inflammation | 3 | 2006 | 2834 | 0.040 |
Why?
| | Nephelometry and Turbidimetry | 2 | 2013 | 13 | 0.040 |
Why?
| | Tyrosine | 1 | 2000 | 222 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2021 | 316 | 0.040 |
Why?
| | Luminescent Measurements | 2 | 2013 | 75 | 0.040 |
Why?
| | Granuloma, Respiratory Tract | 1 | 1999 | 12 | 0.040 |
Why?
| | Receptors, Cytokine | 1 | 1999 | 36 | 0.040 |
Why?
| | Xenobiotics | 1 | 1999 | 32 | 0.040 |
Why?
| | Receptors, Interferon | 1 | 1999 | 51 | 0.040 |
Why?
| | Steroid 21-Hydroxylase | 1 | 1999 | 30 | 0.040 |
Why?
| | Cytokines | 1 | 2007 | 2088 | 0.040 |
Why?
| | Addison Disease | 1 | 1999 | 43 | 0.040 |
Why?
| | Viral Tropism | 1 | 2018 | 30 | 0.040 |
Why?
| | Antigens, CD34 | 2 | 2013 | 88 | 0.040 |
Why?
| | Metallothionein | 1 | 1998 | 25 | 0.040 |
Why?
| | Antibodies, Monoclonal | 3 | 1991 | 1428 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 152 | 0.040 |
Why?
| | Immunoglobulin M | 2 | 1991 | 288 | 0.040 |
Why?
| | Virus Activation | 1 | 2018 | 87 | 0.040 |
Why?
| | Virus Latency | 1 | 2018 | 81 | 0.040 |
Why?
| | Pokeweed Mitogens | 2 | 1988 | 7 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2018 | 75 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 556 | 0.040 |
Why?
| | Depression, Chemical | 1 | 1997 | 23 | 0.040 |
Why?
| | Mycophenolic Acid | 1 | 1998 | 117 | 0.030 |
Why?
| | Acute Lung Injury | 1 | 2020 | 288 | 0.030 |
Why?
| | Drug Therapy, Combination | 2 | 1998 | 1059 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2005 | 2831 | 0.030 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 1 | 1997 | 31 | 0.030 |
Why?
| | 3T3 Cells | 1 | 1997 | 163 | 0.030 |
Why?
| | Insulin, Long-Acting | 1 | 1997 | 63 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 495 | 0.030 |
Why?
| | New York | 1 | 1997 | 129 | 0.030 |
Why?
| | Guanidines | 1 | 1996 | 40 | 0.030 |
Why?
| | Sulfhydryl Compounds | 2 | 1991 | 191 | 0.030 |
Why?
| | Contraindications | 1 | 2016 | 90 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 139 | 0.030 |
Why?
| | Complement Activation | 1 | 2019 | 411 | 0.030 |
Why?
| | S Phase | 1 | 1996 | 77 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2021 | 6046 | 0.030 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2016 | 54 | 0.030 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 2015 | 7 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 205 | 0.030 |
Why?
| | Half-Life | 2 | 1996 | 165 | 0.030 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 2015 | 20 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 268 | 0.030 |
Why?
| | Liver | 3 | 2007 | 1938 | 0.030 |
Why?
| | Desensitization, Immunologic | 1 | 2016 | 94 | 0.030 |
Why?
| | B-Lymphocyte Subsets | 1 | 2015 | 75 | 0.030 |
Why?
| | Cross Reactions | 3 | 1990 | 133 | 0.030 |
Why?
| | Antigens, Viral, Tumor | 1 | 1994 | 7 | 0.030 |
Why?
| | Antigens, CD19 | 1 | 2015 | 123 | 0.030 |
Why?
| | Iron | 1 | 1997 | 311 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1994 | 150 | 0.030 |
Why?
| | Genetic Loci | 1 | 2016 | 288 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2016 | 178 | 0.030 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2007 | 27 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2001 | 1309 | 0.030 |
Why?
| | Prevalence | 1 | 2001 | 2712 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 357 | 0.030 |
Why?
| | Mice, Inbred DBA | 2 | 1992 | 200 | 0.030 |
Why?
| | Thioguanine | 1 | 2013 | 19 | 0.030 |
Why?
| | Cell Adhesion | 1 | 1994 | 467 | 0.030 |
Why?
| | Immunization, Passive | 1 | 1993 | 90 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2013 | 150 | 0.020 |
Why?
| | Survivors | 1 | 2016 | 487 | 0.020 |
Why?
| | Umbilical Cord | 1 | 2013 | 85 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 134 | 0.020 |
Why?
| | Drug Resistance | 1 | 2013 | 169 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2024 | 7569 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 224 | 0.020 |
Why?
| | Survival Analysis | 2 | 2012 | 1319 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2013 | 147 | 0.020 |
Why?
| | Anticoagulants | 1 | 2016 | 658 | 0.020 |
Why?
| | Mice, Inbred C57BL | 3 | 2011 | 5744 | 0.020 |
Why?
| | Mercaptopurine | 1 | 1991 | 16 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2012 | 163 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2190 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3399 | 0.020 |
Why?
| | Lymphoma | 1 | 2012 | 206 | 0.020 |
Why?
| | Signal Transduction | 2 | 2021 | 5065 | 0.020 |
Why?
| | Blood Donors | 1 | 2011 | 103 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2006 | 654 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 356 | 0.020 |
Why?
| | Glucose | 1 | 1994 | 1019 | 0.020 |
Why?
| | Methylmannosides | 1 | 1989 | 1 | 0.020 |
Why?
| | Cytochalasins | 1 | 1989 | 3 | 0.020 |
Why?
| | Rosette Formation | 1 | 1989 | 16 | 0.020 |
Why?
| | Colchicine | 1 | 1989 | 23 | 0.020 |
Why?
| | Fetus | 1 | 2013 | 806 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1768 | 0.020 |
Why?
| | Monocytes | 2 | 1989 | 561 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1942 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2011 | 843 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1992 | 324 | 0.020 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2007 | 22 | 0.020 |
Why?
| | Oligoclonal Bands | 1 | 2007 | 20 | 0.020 |
Why?
| | Lipid Peroxides | 1 | 1987 | 10 | 0.020 |
Why?
| | Blood Glucose | 1 | 1997 | 2180 | 0.020 |
Why?
| | DNA Replication | 1 | 1989 | 238 | 0.020 |
Why?
| | Interleukin-6 | 1 | 1991 | 778 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1987 | 177 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2006 | 41 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2030 | 0.020 |
Why?
| | Chemokine CCL8 | 1 | 2006 | 3 | 0.020 |
Why?
| | Monocyte Chemoattractant Proteins | 1 | 2006 | 8 | 0.020 |
Why?
| | Phospholipases A2 | 1 | 2006 | 80 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3272 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2006 | 115 | 0.020 |
Why?
| | DNA, Complementary | 1 | 2005 | 269 | 0.010 |
Why?
| | NADPH Dehydrogenase | 1 | 2005 | 7 | 0.010 |
Why?
| | Cytosol | 1 | 2006 | 226 | 0.010 |
Why?
| | Age Factors | 1 | 2013 | 3290 | 0.010 |
Why?
| | NADH Dehydrogenase | 1 | 2005 | 19 | 0.010 |
Why?
| | Immunity, Cellular | 1 | 1987 | 268 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1987 | 267 | 0.010 |
Why?
| | Chemokine CXCL1 | 1 | 2004 | 76 | 0.010 |
Why?
| | Infant | 3 | 2007 | 9442 | 0.010 |
Why?
| | NADPH Oxidases | 1 | 2005 | 110 | 0.010 |
Why?
| | Translocation, Genetic | 1 | 2005 | 104 | 0.010 |
Why?
| | Blood Transfusion | 1 | 1987 | 324 | 0.010 |
Why?
| | Mice, Inbred AKR | 1 | 1983 | 35 | 0.010 |
Why?
| | Leukemia, Lymphoid | 1 | 1983 | 27 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 1988 | 1062 | 0.010 |
Why?
| | Leukemia, Experimental | 1 | 1983 | 27 | 0.010 |
Why?
| | Lymphokines | 1 | 1983 | 131 | 0.010 |
Why?
| | Acute Disease | 1 | 2006 | 1006 | 0.010 |
Why?
| | Necrosis | 1 | 1984 | 244 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 813 | 0.010 |
Why?
| | Kinetics | 1 | 1986 | 1668 | 0.010 |
Why?
| | Rats | 3 | 2004 | 5628 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1483 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 5718 | 0.010 |
Why?
| | Leukocyte Count | 1 | 2002 | 330 | 0.010 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2000 | 16 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 1991 | 1799 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 12 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | Hematologic Neoplasms | 1 | 2002 | 155 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2002 | 363 | 0.010 |
Why?
| | United States | 1 | 2016 | 14660 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2481 | 0.010 |
Why?
| | Clone Cells | 1 | 1999 | 266 | 0.010 |
Why?
| | Prospective Studies | 3 | 1996 | 7583 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 6731 | 0.010 |
Why?
| | Azathioprine | 1 | 1998 | 54 | 0.010 |
Why?
| | Incidence | 2 | 1995 | 2788 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2002 | 947 | 0.010 |
Why?
| | Prednisone | 1 | 1998 | 243 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 1996 | 59 | 0.010 |
Why?
| | Risk Assessment | 1 | 2006 | 3429 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1996 | 116 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 1996 | 205 | 0.010 |
Why?
| | Risk | 1 | 1999 | 904 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 1996 | 237 | 0.010 |
Why?
| | Dogs | 1 | 1996 | 409 | 0.010 |
Why?
| | Blood Group Incompatibility | 1 | 1995 | 15 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 1995 | 157 | 0.010 |
Why?
| | Species Specificity | 2 | 1988 | 584 | 0.010 |
Why?
| | Diabetic Nephropathies | 1 | 1998 | 293 | 0.010 |
Why?
| | ABO Blood-Group System | 1 | 1995 | 51 | 0.010 |
Why?
| | Cadaver | 1 | 1995 | 295 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 1994 | 408 | 0.010 |
Why?
| | Drug Costs | 1 | 1994 | 106 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 1995 | 622 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 2239 | 0.000 |
Why?
| | Rats, Inbred SHR | 1 | 1988 | 45 | 0.000 |
Why?
| | Deferoxamine | 1 | 1988 | 24 | 0.000 |
Why?
| | Length of Stay | 1 | 1994 | 1208 | 0.000 |
Why?
| | Malondialdehyde | 1 | 1988 | 29 | 0.000 |
Why?
| | Biotransformation | 1 | 1988 | 66 | 0.000 |
Why?
| | Injections, Subcutaneous | 1 | 1988 | 154 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1988 | 329 | 0.000 |
Why?
| | Kidney Cortex | 1 | 1986 | 26 | 0.000 |
Why?
| | Kidney Medulla | 1 | 1986 | 35 | 0.000 |
Why?
| | Administration, Oral | 1 | 1988 | 808 | 0.000 |
Why?
| | Blood Physiological Phenomena | 1 | 1983 | 13 | 0.000 |
Why?
| | Suppressor Factors, Immunologic | 1 | 1983 | 4 | 0.000 |
Why?
| | Mice, Inbred CBA | 1 | 1983 | 54 | 0.000 |
Why?
| | Kidney Diseases | 1 | 1988 | 406 | 0.000 |
Why?
| | Thymidine | 1 | 1983 | 60 | 0.000 |
Why?
| | Rats, Inbred Strains | 1 | 1983 | 361 | 0.000 |
Why?
|
|
Freed's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|